Lee:Literature Proteasomes

Home        Research        Lab Members        Publications        Transporters        Proteasomes        PK/PD/PGx        JC        Links        Internal        Contact       

Feel free to add articles ...

• Recent immunoproteasome papers: PubMed, Cite-U-Like

Proteasome Biology general review

1. Hoeller D and Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009 Mar 26;458(7237):438-44. DOI:10.1038/nature07960 |
2. Mani A and Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005 Jul 20;23(21):4776-89. DOI:10.1200/JCO.2005.05.081 |
3. Murata S, Yashiroda H, and Tanaka K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol. 2009 Feb;10(2):104-15. DOI:10.1038/nrm2630 |

Immunoproteasome

1. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, and Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum. 2007 Mar;50(3):337-48; discussion 348-50. DOI:10.1007/s10350-006-0796-7 |
2. Gavilán MP, Castaño A, Torres M, Portavella M, Caballero C, Jiménez S, García-Martínez A, Parrado J, Vitorica J, and Ruano D. Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J Neurochem. 2009 Jan;108(1):260-72. DOI:10.1111/j.1471-4159.2008.05762.x |
3. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 |
4. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, and Kim KB. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007 Apr;14(4):419-30. DOI:10.1016/j.chembiol.2007.03.008 |
5. Heink S, Fricke B, Ludwig D, Kloetzel PM, and Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. DOI:10.1158/0008-5472.CAN-05-2872 |
6. Namiki S, Nakamura T, Oshima S, Yamazaki M, Sekine Y, Tsuchiya K, Okamoto R, Kanai T, and Watanabe M. IRF-1 mediates upregulation of LMP7 by IFN-gamma and concerted expression of immunosubunits of the proteasome. FEBS Lett. 2005 May 23;579(13):2781-7. DOI:10.1016/j.febslet.2005.04.012 |
7. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi S, Pession A, Ohm T, Grune T, and Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging. 2006 Jan;27(1):54-66. DOI:10.1016/j.neurobiolaging.2004.12.004 |
8. Mishto M, Luciani F, Holzhütter HG, Bellavista E, Santoro A, Textoris-Taube K, Franceschi C, Kloetzel PM, and Zaikin A. Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J Mol Biol. 2008 Apr 11;377(5):1607-17. DOI:10.1016/j.jmb.2008.01.086 |
9. Mishto M, Bonafè M, Salvioli S, Olivieri F, and Franceschi C. Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp Gerontol. 2002 Jan-Mar;37(2-3):301-8. DOI:10.1016/s0531-5565(01)00196-6 |
10. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, and Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004 Mar 20;109(2):265-73. DOI:10.1002/ijc.11681 |
11. Visekruna A, Joeris T, Schmidt N, Lawrenz M, Ritz JP, Buhr HJ, and Steinhoff U. Comparative expression analysis and characterization of 20S proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for IBD patients. Inflamm Bowel Dis. 2009 Apr;15(4):526-33. DOI:10.1002/ibd.20805 |
12. Tu L, Moriya C, Imai T, Ishida H, Tetsutani K, Duan X, Murata S, Tanaka K, Shimokawa C, Hisaeda H, and Himeno K. Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection. Eur J Immunol. 2009 Dec;39(12):3385-94. DOI:10.1002/eji.200839117 |

LMP2/7

1. Griffin TA, Nandi D, Cruz M, Fehling HJ, Kaer LV, Monaco JJ, and Colbert RA. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med. 1998 Jan 5;187(1):97-104. DOI:10.1084/jem.187.1.97 |
2. De M, Jayarapu K, Elenich L, Monaco JJ, Colbert RA, and Griffin TA. Beta 2 subunit propeptides influence cooperative proteasome assembly. J Biol Chem. 2003 Feb 21;278(8):6153-9. DOI:10.1074/jbc.M209292200 |
3. Schmidt M, Zantopf D, Kraft R, Kostka S, Preissner R, and Kloetzel PM. Sequence information within proteasomal prosequences mediates efficient integration of beta-subunits into the 20 S proteasome complex. J Mol Biol. 1999 Apr 23;288(1):117-28. DOI:10.1006/jmbi.1999.2660 |
4. Enenkel C, Lehmann A, and Kloetzel PM. GFP-labelling of 26S proteasomes in living yeast: insight into proteasomal functions at the nuclear envelope/rough ER. Mol Biol Rep. 1999 Apr;26(1-2):131-5. DOI:10.1023/a:1006973803960 |
5. Reits EA, Benham AM, Plougastel B, Neefjes J, and Trowsdale J. Dynamics of proteasome distribution in living cells. EMBO J. 1997 Oct 15;16(20):6087-94. DOI:10.1093/emboj/16.20.6087 |
6. Cai ZP, Shen Z, Van Kaer L, and Becker LC. Ischemic preconditioning-induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide-2 deficiency. FASEB J. 2008 Dec;22(12):4248-57. DOI:10.1096/fj.08-105940 |
7. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, and Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med. 2009 Jul;15(7):781-7. DOI:10.1038/nm.1978 |

NF-kB

1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, and Sethi G. Inflammation and cancer: how hot is the link?. Biochem Pharmacol. 2006 Nov 30;72(11):1605-21. DOI:10.1016/j.bcp.2006.06.029 |
2. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006 May 25;441(7092):431-6. DOI:10.1038/nature04870 |
3. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62. DOI:10.1038/nrm2083 |
4. Debruyne PR, Witek M, Gong L, Birbe R, Chervoneva I, Jin T, Domon-Cell C, Palazzo JP, Freund JN, Li P, Pitari GM, Schulz S, and Waldman SA. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006 Apr;130(4):1191-206. DOI:10.1053/j.gastro.2005.12.032 |

MDR1 & apoptosis, NF-kB

1. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, Gielen J, Merville MP, and Bours V. NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003 Jan 9;22(1):90-7. DOI:10.1038/sj.onc.1206056 |
2. Pallis M and Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood. 2000 May 1;95(9):2897-904.
3. Smyth MJ, Krasovskis E, Sutton VR, and Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7024-9. DOI:10.1073/pnas.95.12.7024 |
4. Johnstone RW, Cretney E, and Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood. 1999 Feb 1;93(3):1075-85.
5. Patel VA, Dunn MJ, and Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002 Oct 11;277(41):38915-20. DOI:10.1074/jbc.M206855200 |